Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`PTO Form 1960 (Rev 10/2011)
`
`OMB No. 0651-0050 (Exp 09/20/2020)
`
`Request for Reconsideration after Final Action
`
`The table below presents the data as entered.
`
`Input Field
`
`SERIAL NUMBER
`
`87348269
`
`LAW OFFICE
`ASSIGNED
`
`MARK SECTION
`
`LAW OFFICE 118
`
`Entered
`
`MARK FILE NAME
`
`https://tmng-al.uspto.gov/resting2/api/img/87348269/large
`
`LITERAL ELEMENT
`
`STANDARD CHARACTERS
`
`A
`
`NO
`
`USPTO-GENERATED IMAGE NO
`
`EVIDENCE SECTION
`
`        EVIDENCE FILE NAME(S)
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._Request_for_Reconsideration.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (15 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0002.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0003.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0004.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0005.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0006.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0007.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0008.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0009.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0010.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0011.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0012.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0013.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0014.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0015.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0016.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__4635110.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (7 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0017.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0018.JPG
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0019.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0020.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0021.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0022.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0023.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__4303858.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0024.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0025.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__5127573.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0026.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0027.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__2905870.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (1 page)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0028.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__4141225.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0029.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0030.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__4027346.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0031.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0032.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__5488639.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0033.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0034.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__5078898.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0035.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0036.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__3810214.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (1 page)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0037.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4924974.pdf
`
`       CONVERTED PDF
`FILE(S)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0038.JPG
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`       (3 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0039.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0040.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration__No__4907938.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0041.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0042.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4859400.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0043.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0044.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4781976.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0045.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0046.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4260076.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0047.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0048.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._File_History_for_Application_No__79222881.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (4 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0049.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0050.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0051.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0052.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._File_History_for_Application_No__87927618.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0053.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0054.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4555231.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (3 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0055.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0056.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0057.JPG
`
`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4162214.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (2 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0058.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0059.JPG
`
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`       
`

`

`       ORIGINAL PDF FILE
`
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4635110.pdf
`
`       CONVERTED PDF
`FILE(S)
`       (7 pages)
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0060.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0061.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0062.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0063.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0064.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0065.JPG
`
`\\TICRS\EXPORT17\IMAGEOUT17\873\482\87348269\xml8\RFR0066.JPG
`
`DESCRIPTION OF EVIDENCE
`FILE
`
`Request for Reconsideration; Certificates of Registrations
`
`GOODS AND/OR SERVICES SECTION (current)
`
`INTERNATIONAL CLASS
`
`005
`
`DESCRIPTION
`
`prescription pharmaceutical products for a variety of diseases
`
`FILING BASIS
`
`Section 1(b)
`
`GOODS AND/OR SERVICES SECTION (proposed)
`
`INTERNATIONAL CLASS
`
`005
`
`TRACKED TEXT DESCRIPTION
`
`prescription pharmaceutical products for a variety of diseases; Pharmaceutical preparations and substances for the treatment of viral,
`metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological,
`ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and
`disorders; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for
`treating respiratory diseases and asthma; Pharmaceutical products for the prevention and treatment of cancer; Dermatological pharmaceutical
`products; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of joint disease; Intravenous fluids
`used for rehydration, nutrition and the delivery of pharmaceutical preparations; Intravenous bags, syringes, and vials sold filled with injectable
`pharmaceutical preparations, namely, oncologic products and ancillary products, chemotherapy agents, anti-emitics, and anti-infectives;
`Anticholinergics; Anticholinesterases; Anti-hypotensives; Biological preparations for the treatment of cancer; Anesthetics for surgical and
`non-surgical use; Antibiotics; Antiemetics; Analgesics; Sedatives; Dietary supplements; Vaccines; Blood for medical purposes; all of the
`foregoing featuring differentiated packaging for the purpose of reducing user errors and promoting correct medication selection
`
`FINAL DESCRIPTION
`
`Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary,
`genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal,
`dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for the treatment of viral and
`infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical products
`for the prevention and treatment of cancer; Dermatological pharmaceutical products; Pharmaceutical products for ophthalmological use;
`Pharmaceutical products for the treatment of joint disease; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical
`preparations; Intravenous bags, syringes, and vials sold filled with injectable pharmaceutical preparations, namely, oncologic products and
`ancillary products, chemotherapy agents, anti-emitics, and anti-infectives; Anticholinergics; Anticholinesterases; Anti-hypotensives;
`Biological preparations for the treatment of cancer; Anesthetics for surgical and non-surgical use; Antibiotics; Antiemetics; Analgesics;
`Sedatives; Dietary supplements; Vaccines; Blood for medical purposes; all of the foregoing featuring differentiated packaging for the purpose
`of reducing user errors and promoting correct medication selection
`
`FILING BASIS
`
`Section 1(b)
`
`SIGNATURE SECTION
`
`RESPONSE SIGNATURE
`
`/Jacqueline M. Lesser/
`
`SIGNATORY'S NAME
`
`       
`       
`       
`       
`       
`       
`

`

`SIGNATORY'S NAME
`
`Jacqueline M. Lesser
`
`SIGNATORY'S POSITION
`
`Attorney of record, PA and NY bar member
`
`SIGNATORY'S PHONE
`NUMBER
`
`DATE SIGNED
`
`215.564.2155
`
`06/13/2018
`
`AUTHORIZED SIGNATORY
`
`CONCURRENT APPEAL
`NOTICE FILED
`
`YES
`
`NO
`
`FILING INFORMATION SECTION
`
`SUBMIT DATE
`
`Wed Jun 13 12:06:03 EDT 2018
`
`TEAS STAMP
`
`USPTO/RFR-XX.XX.XXX.XXX-2
`0180613120603163465-87348
`269-610cce56ae4c130751fa6
`f86365546fb7935a84d48488c
`6a19d139af1a9b06c-N/A-N/A
`-20180613115646602625
`
`Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`PTO Form 1960 (Rev 10/2011)
`
`OMB No. 0651-0050 (Exp 09/20/2020)
`
`Request for Reconsideration after Final Action
`To the Commissioner for Trademarks:
`
`Application serial no. 87348269 A (Stylized and/or with Design, see https://tmng-al.uspto.gov/resting2/api/img/87348269/large) has been
`amended as follows:
`
`EVIDENCE
`Evidence in the nature of Request for Reconsideration; Certificates of Registrations has been attached.
`Original PDF file:
`evi_3898219243-20180613085846101791_._Request_for_Reconsideration.pdf
`Converted PDF file(s) ( 15 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Evidence-4
`Evidence-5
`Evidence-6
`Evidence-7
`Evidence-8
`Evidence-9
`Evidence-10
`Evidence-11
`Evidence-12
`Evidence-13
`Evidence-14
`Evidence-15
`Original PDF file:
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__4635110.pdf
`Converted PDF file(s) ( 7 pages)
`Evidence-1
`Evidence-2
`
`

`

`Evidence-3
`Evidence-4
`Evidence-5
`Evidence-6
`Evidence-7
`Original PDF file:
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__4303858.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__5127573.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__2905870.pdf
`Converted PDF file(s) ( 1 page)
`Evidence-1
`Original PDF file:
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__4141225.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__4027346.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__5488639.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__5078898.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613085846101791_._U_S__Trademark_Certificate_of_Registration_No__3810214.pdf
`Converted PDF file(s) ( 1 page)
`Evidence-1
`Original PDF file:
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4924974.pdf
`Converted PDF file(s) ( 3 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Original PDF file:
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration__No__4907938.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4859400.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`
`

`

`Original PDF file:
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4781976.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4260076.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613094730127628_._File_History_for_Application_No__79222881.pdf
`Converted PDF file(s) ( 4 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Evidence-4
`Original PDF file:
`evi_3898219243-20180613094730127628_._File_History_for_Application_No__87927618.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4555231.pdf
`Converted PDF file(s) ( 3 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Original PDF file:
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4162214.pdf
`Converted PDF file(s) ( 2 pages)
`Evidence-1
`Evidence-2
`Original PDF file:
`evi_3898219243-20180613094730127628_._U_S__Trademark_Certificate_of_Registration_No__4635110.pdf
`Converted PDF file(s) ( 7 pages)
`Evidence-1
`Evidence-2
`Evidence-3
`Evidence-4
`Evidence-5
`Evidence-6
`Evidence-7
`
`CLASSIFICATION AND LISTING OF GOODS/SERVICES
`Applicant proposes to amend the following class of goods/services in the application:
`Current: Class 005 for prescription pharmaceutical products for a variety of diseases
`Original Filing Basis:
`Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a
`bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services in the application. For a
`collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a
`bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with
`the identified goods/services/collective membership organization. For a certification mark application: As of the application filing date, the
`applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in
`connection with the identified goods/services, and the applicant will not engage in the production or marketing of the goods/services to which the
`mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification
`standards of the applicant.
`
`Proposed:
`Tracked Text Description: prescription pharmaceutical products for a variety of diseases; Pharmaceutical preparations and substances for the
`
`

`

`treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological,
`hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases
`and disorders; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for
`treating respiratory diseases and asthma; Pharmaceutical products for the prevention and treatment of cancer; Dermatological pharmaceutical
`products; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of joint disease; Intravenous fluids used
`for rehydration, nutrition and the delivery of pharmaceutical preparations; Intravenous bags, syringes, and vials sold filled with injectable
`pharmaceutical preparations, namely, oncologic products and ancillary products, chemotherapy agents, anti-emitics, and anti-infectives;
`Anticholinergics; Anticholinesterases; Anti-hypotensives; Biological preparations for the treatment of cancer; Anesthetics for surgical and non-
`surgical use; Antibiotics; Antiemetics; Analgesics; Sedatives; Dietary supplements; Vaccines; Blood for medical purposes; all of the foregoing
`featuring differentiated packaging for the purpose of reducing user errors and promoting correct medication selection
`
`Class 005 for Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular,
`cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal,
`dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for the treatment of viral and infectious
`diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical products for the
`prevention and treatment of cancer; Dermatological pharmaceutical products; Pharmaceutical products for ophthalmological use; Pharmaceutical
`products for the treatment of joint disease; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations;
`Intravenous bags, syringes, and vials sold filled with injectable pharmaceutical preparations, namely, oncologic products and ancillary products,
`chemotherapy agents, anti-emitics, and anti-infectives; Anticholinergics; Anticholinesterases; Anti-hypotensives; Biological preparations for the
`treatment of cancer; Anesthetics for surgical and non-surgical use; Antibiotics; Antiemetics; Analgesics; Sedatives; Dietary supplements;
`Vaccines; Blood for medical purposes; all of the foregoing featuring differentiated packaging for the purpose of reducing user errors and
`promoting correct medication selection
`Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a
`bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services in the application. For a
`collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a
`bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with
`the identified goods/services/collective membership organization. For a certification mark application: As of the application filing date, the
`applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in
`connection with the identified goods/services, and the applicant will not engage in the production or marketing of the goods/services to which the
`mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification
`standards of the applicant.
`
`SIGNATURE(S)
`Request for Reconsideration Signature
`Signature: /Jacqueline M. Lesser/     Date: 06/13/2018
`Signatory's Name: Jacqueline M. Lesser
`Signatory's Position: Attorney of record, PA and NY bar member
`
`Signatory's Phone Number: 215.564.2155
`
`The signatory has confirmed that he/she is an attorney who is a member in good standing of the bar of the highest court of a U.S. state, which
`includes the District of Columbia, Puerto Rico, and other federal territories and possessions; and he/she is currently the owner's/holder's attorney
`or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another U.S. attorney or a Canadian attorney/agent
`not currently associated with his/her company/firm previously represented the owner/holder in this matter: (1) the owner/holder has filed or is
`concurrently filing a signed revocation of or substitute power of attorney with the USPTO; (2) the USPTO has granted the request of the prior
`representative to withdraw; (3) the owner/holder has filed a power of attorney appointing him/her in this matter; or (4) the owner's/holder's
`appointed U.S. attorney or Canadian attorney/agent has filed a power of attorney appointing him/her as an associate attorney in this matter.
`
`The applicant is not filing a Notice of Appeal in conjunction with this Request for Reconsideration.
`
`Serial Number: 87348269
`Internet Transmission Date: Wed Jun 13 12:06:03 EDT 2018
`TEAS Stamp: USPTO/RFR-XX.XX.XXX.XXX-2018061312060316
`3465-87348269-610cce56ae4c130751fa6f8636
`5546fb7935a84d48488c6a19d139af1a9b06c-N/
`A-N/A-20180613115646602625
`
`        
`

`

`In re:
`
`Trademark Application of
`Athenex. Inc.
`
`Serial No.:
`
`87/348269
`
`Filed:
`
`February 24, 2017
`
`For:
`
`A Design
`
`Law Office 1 l8
`
`REQUEST FOR RECONSIDERATION
`
`This responds to the Office Action dated December 14. 2017. The Applicant has entered an
`amendment to the specification of goods in accordance with the Trademark Examining
`Attorney’ s requirements.
`
`Applicant respectfully disagrees with the Trademark Examining Attorney’s continued
`characterization of Applicant” s mark as confusing with the cited prior registration for AX. There
`is no evidence in the record that the parties” respective marks have similar commercial
`impressions.
`
`The Trademark Office in its initial characterization of the literal elements of the mark has
`
`characterized the mark as an A mark. Although the stylized mark of Applicant is clearly an
`“A” and the tail at the end could be considered an x (mirroring Applicant‘s name. Athenex),
`there is no reason to conclude that consumers would consider it as an AX, and in particular no
`evidence of record that the relevant consuming public would consider the stylized mark to be a
`“play” on Rx. 7 its highly stylized mark could be viewed as the first letter and last letter of
`Applicant’s name i Athenex i that counters any argument that consumers would view the mark
`as a play on Rx. In prosecution. it is the Trademark Examining Attorney’s burden to make the
`leap i concluding that both marks although clearly not identical 7 would be perceived as
`confusingly similar. The Trademark Examining Attorney offers no evidence that a
`pharmaceutical mark of any kind 7 which is composed of two letters 7 the second of which is as
`X would be considered by the consuming public to give the impression of the term Rx.
`
`There is in fact no reason that a consumer would look at the mark as an AX mark at all 7 except
`if the consumer connects the mark with Applicant’s highly stylized logo for Athenex. The
`design of the mark may from a purely design perspective be evocative of two letters — but the
`stylization is so completely different from the cited registration, or from an impression of an AX
`generally as to be insignificant.
`It is the commercial impression of the mark in the marketplace
`that is significant only,
`
`Indeed. there are many stylized A marks on the Register that are for pharmaceutical products.
`There are many companies that have an A and an X as part of their names. The coexistence of
`all of these marks on the register shows clearly that the commercial impressions of stylized A
`marks that have possible X elements are considered. commercially distinct and non-confusing
`marks. For example:
`
`

`

`
`
`Status/Key
`Mark/Name/ Design
`AN/RN
`Descriptio Dates
`
`11
`
`Brief Goods/Services
`
`Owner Information
`
`A (Stylized!
`
`EnglishTH Registered
`E MARK
`June 19, 2012
`CONSIST
`Int'l Class:
`
`S OF THE 42,44
`STYLIZE
`First Use:
`
`D
`LETTER
`
`"A".:
`
`RN: 4162214
`SN:
`85293403
`
`September
`11, 2011
`
`Filed: April
`12, 201 1
`Registered:
`June 19, 2012
`
`Astex Pharmaceuticals, Inc.
`(Delaware Corp.)
`4140 Dublin Blvd. Suite 200
`
`Dublin California 94568
`
`(lnt'l Class: 42)
`research and development
`services in the field of
`
`pharmaceuticals; providing
`medical and scientific health
`
`care research information in the
`field...
`
`(Int'l Class: 44)
`providing health care
`infonnation via telephone and
`the internet; providing
`information in the field of the
`
`diagnostic, prophylactic, and
`therapeutic. .
`.
`
`
`Alnylam Phainiaceuticals,
`(lnt'l Class: 05)
`Inc. (Delaware Corp.)
`pharmaceutical preparations,
`namely, rna therapeutics for use 300 Third Street, 3rd Floor
`in the treatment of cancer, hiv,
`Cambridge Massachusetts
`hepatitis a, hepatitis b,
`02142
`influenza, measles,
`
`
`
`
`
`
`
`
`
`A (Stylized!
`
`‘
`
`RN: 455523 1
`SN:
`86093 883
`
`A (Stylized!
`
`'32/
`
`EnglishTH Pending -
`E MARK
`Initialized
`CONSIST May 22, 2018
`S OF A
`Filed: May
`STYLIZE
`18, 2018
`D
`
`LETTER
`"A " . ;
`
`
`
`Avamere Group, LLC
`(lnt'l Class: 43)
`EnglishTH Registered
`(Oregon Limited Liability
`E MARK
`June 24, 2014 providing assisted and
`Company)
`CONSIST
`Int'l Class:
`independent living facilities;
`Suite B 25117 Sw Parkway
`S OF A
`43,44,45
`retirement homes; providing
`STYLIZE
`First Use:
`short and long-term residential Wilsonville Oregon 97070
`D
`January 1,
`services for the elderly
`LETTER
`2000
`(Int'l Class: 44)
`"A".;
`Filed:
`nursing care; home nursing aid
`ggltzber 17,
`services; nursing homes;
`.
`T
`prOVlCllilg physical .
`Registered:
`rehabilitation facilities; nursnig,
`June 24, 2014 physical, occupational and
`speech therapy; home health...
`(Int'l Class: 45)
`providing personal support
`services for families ofpatients
`with life threatening disorders,
`namely. companionship,
`counseling and emotional
`support; grief counseling...
`
`
`
`neurodegenerative diseases,
`transthyretin (ttr) -me diated
`SN:
`amyloidosis (attr), hemophilia.
`87927618
`
`
`

`

`
`
`porphyria, complement-
`mediated disease,
`
`hypercholesterolemia; rare
`genetic diseases; cardio-
`metabolic diseases, hepatic
`infectious diseases, hereditary
`attr...
`
`bleaching preparations for
`laundry use; cleaning,
`polishing, scouring and
`abrasive preparations; non-
`medicated soaps; perfumery,
`essential oils, cosmetics; hair
`lotions; dentifrices
`
`(Int'l Class: 09)
`eyewear; protective eyewear;
`sports eyewear; eyewear for
`cycling; triathlon eyewear;
`eyewear for swimming;
`eyewear cases; sun glasses;
`lenses for glasses;...
`(Int'l Class: 12)
`land vehicles; apparatus for
`locomotion by land, air or
`water; namely; bicycles and
`structural parts therefore
`(Int'l Class: 18)
`luggage; suitcases; bags;
`namely; all-purpose athletic
`bags; book bags; gym bags,
`cany-on bags, duffel bags, gym
`bags; shoulder bags; tote...
`(Int'l Class: 28)
`protective padding for cycling;
`protective padding for use in
`cycling shorts
`(Int'l Class: 35)
`retail store and Wholesale store
`
`Publication
`Review
`
`Complete
`June 26; 2018
`
`Filed: August
`4; 2017
`
`Int'l Reg
`Date: August
`4; 2017
`
`E MARK
`CONSIST
`S OF A
`FANCIFU
`
`L P
`
`RESENT
`ATION
`OF THE
`LETTER
`"A" SET
`FORTH
`IN A
`LARGE
`BLOCK
`
`FONT;
`
`SN:
`79222881
`
`
`
`sen'ices relating to bleaching
`preparations and other
`substances for 'laundly use;
`cleaning and fragrancing
`
`preparations. ..
`
`
`
`
`
`(Switzerland Gesellschaft
`Mit Beschrankter Haftung
`(Gmbh))
`Via Bresce 1 (311-6854 San
`Pietro Di Stabio Switzerland
`
`
`
`
`
` A [Stylizedl EnglishTH Pending - (Int'l Class: 03) Assos of Switzerland GmbH
`
`

`

`
`
`
`
`A and Design EnglishTH
`E MARK
`
`RN: 4260076
`.
`85N412756
`
`Registered
`December 18,
`2012
`Int'l Class: 35
`S OF A
`First Use:
`STYLIZE
`Au
`'t 15
`D
`gus
`2009
`LETTER
`"A" WITH Filed:
`A
`September 1,
`REPRESE 2011
`
`,
`
`NTATION Registered:
`OF A
`December 18,
`STREAMI
`2012
`
`(Int'l Class: 35)
`management of a
`pharmaceutical drug program
`for eligible healthcare facilities,
`namely, pharmaceutical cost
`t
`d
`n' t'
`managemen an neg: 1a 111g
`pricing and purchasing
`pharmaceutical products for
`others
`
`Vizient Supply, LLC
`(Delaware Limited Liability
`Company)
`290 East John Carpenter
`Freeway Iwillg Texas 75062
`
`NG TAIL;
`
`
`(Int'l Class: 05)
`A and Design EnglishTH Registered.
`E MARK
`July 28, 2015 Vitamin a dietary and
`CONSIST
`Int'l Class: 05
`nutritional supplements
`S OF THE First Use:
`9
`0 STYLIZE December 2,
`D
`2014
`LETTER
`Filed:
`"A" WITH December 18,
`A SWIRL
`2014
`ENDING
`Registered:
`WITH
`July 28, 2015
`TWO
`LEAVES
`ON THE
`RIGHT
`
`RN: 4781976
`SN:
`86484900
`
`A and Design EnglishTH Registered
`E MARK
`November
`CONSIST
`24, 2015
`
`SIDE;
`
`/ S OF 5
`/ LINES IN
`
`THE
`OVERAL
`
`Int'l Class: 05
`FirstUse:
`
`Febiualy 1 1,
`1991
`
`(Int'l Class: 05)
`pharmaceuticals for parenteral
`nutrition
`
` V CONSIST
`
`
`
`
`
`
`
`
`
`Alife Pharmaceutical, Inc.
`(New York Corp.)
`136-20 38th Avenue, Suite
`9H Flushing New York
`11354
`
`Aguettant Sante (France
`Sociéte Anonyme (Sa))
`Parc Scientifique Tony
`
`Garnier 1 Rue Alexander
`Fleming Lyon 69007 France
`
`
`
`Filed: April
`L
`_
`L
`22, 2015
`IMPRESSI
`§§ 485)400
`Registered:
`ON OF A
`
`86605477
`
`

`

`
`
`HIGHLY
`STYLIZE
`
`November
`
`24, 2015
`
`D "A",
`WITH 2
`DIAGON
`AL LINES
`CURVING
`UP FROM
`LEFT TO
`RIGHT
`ON THE
`FAR
`
`LEFT,
`ONE
`LARGE
`VERTICA
`L LINE
`INTERSE
`CTED BY
`A LINE IN
`THE
`MIDDLE
`AND ONE
`DIAGON
`AL LINE
`MOVING
`UP FROM
`LEFT TO
`RIGHT
`ON THE
`RIGHT
`SIDE OF
`THE
`
`DESIGN;
`
`IA
`
`March 1,
`2016
`Int'l Class: 05
`First Use:
`
`October 31,
`2014
`Filed: June
`
`
`
` A and Design EnglishTH Registered (Int'l Class: 05) Api Usa, LLC (New
`
`
`
`
`
`dietary and nutritional
`supplements
`
`
`
`Hampshire Limited Liability
`Company)
`55 Clystal Avenue, Unit 7,
`Suite 115 Derry New
`Hampshire 03038
`
`
`
`E MARK
`CONSIST
`S OF THE
`LETTER
`"A" WITH
`A SLANT
`LINE
`IMAGE
`18, 2015
`RN: 4907938
`IN
`
`Registered:
`
`

`

`
`
`SN:
`86667099
`
`FRONT
`OF THE
`
`March 1,
`2016
`
`”A” -;
`
`
`March 29,
`2016
`Filed:
`
`September
`20, 2013
`
`Registered:
`March 29,
`2016
`
` Registered
`
` EnglishTH
`
`E MARK
`CONSIST
`S OF 5
`BLUE
`LINES IN
`THE
`OVERAL
`
`L I
`
`MPRESSI
`ON OF A
`HIGHLY
`STYLIZE
`
`D ”A”,
`WITH 2
`DIAGON
`AL LINES
`CURVING
`UP FROM
`LEFT TO
`RIGHT
`ON THE
`FAR
`
`//
`
`RN: 4924974
`SN:
`86070477
`
` A and Design
`
`LEFT,
`ONE
`LARGE
`VERTICA
`L LINE
`INTERSE